##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 6 (2025)

Long-term impacts of Legionnaires’ disease on health and wellbeing: rationale, study design and baseline findings of a matched cohort study (LongLEGIO)

Cite this as:
Swiss Med Wkly. 2025;155:4333
Published
17.06.2025

Summary

BACKGROUND AND STUDY AIMS: Is there a post-acute infection syndrome for Legionnaires’ disease? Legionnaires’ disease is a form of primarily community-acquired pneumonia caused by Legionella spp. bacteria. Legionnaires’ disease and other forms of bacterial community-acquired pneumonia may lead to persistent health and wellbeing impairments. It remains unclear whether these are caused by the community-acquired pneumonia-causing pathogen or the pneumonia itself. We present the rationale and design of a matched cohort study to investigate the persistent health impacts of Legionnaires’ disease and compare them with persistent manifestations of other bacterial (Legionella test-negative) community-acquired pneumonia. We also present baseline characteristics of the study cohorts.

METHODS: Legionnaires’ disease patients and Legionella test-negative community-acquired pneumonia patients with confirmed or clinically suspected bacterial aetiology were recruited from university and cantonal/regional hospitals and matched for sex, age, hospital type and date of diagnosis. Questionnaire-based interviews are conducted at baseline and 2, 6 and 12 months after the start of appropriate antibiotics. The questionnaires focus on patient-reported outcome measures and cover long-term symptoms, use of health services and health-related quality of life.

RESULTS: Between June 2023 and June 2024, 59 patients with Legionnaires’ disease (59.3% male, median age 69 years [interquartile range [IQR]: 57–80]) and 60 patients with other bacterial (Legionella test-negative) community-acquired pneumonia (63.3% male, median age 69 years [IQR: 60–79]) were enrolled. Admission to the intensive care unit was required for 13.6 % of Legionnaires’ disease patients and 8.3 % of other bacterial community-acquired pneumonia patients. Chronic kidney failure was more prevalent among Legionnaires’ disease patients (15.3% vs 10.0%), while chronic obstructive pulmonary disease (20.0% vs 11.9%), malignancies (33.3% vs 13.6%) and an immunocompromised status (25.0% vs 13.6%) were more common in Legionella test-negative community-acquired pneumonia patients. Furthermore, Legionella test-negative community-acquired pneumonia patients reported lower baseline quality of life scores than Legionnaires’ disease patients. Differences in pneumonia severity, comorbidities and self-reported quality of life scores will be accounted for in future analyses.

CONCLUSIONS: The LongLEGIO study will contribute to research on post-acute infection syndromes and provide the data for a more holistic assessment of the disease burden of Legionnaires’ disease.

References

  1. Bender RG, Sirota SB, Swetschinski LR, et al.; GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis. 2024 Sep;24(9):974–1002. doi: https://doi.org/10.1016/S1473-3099(24)00176-2
  2. World Health Organization. Global Health Estimates. Available from: https://www.who.int/data/global-health-estimates
  3. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012 Jan;67(1):71–9. doi: https://doi.org/10.1136/thx.2009.129502
  4. Adamuz J, Viasus D, Campreciós-Rodríguez P, Cañavate-Jurado O, Jiménez-Martínez E, Isla P, et al. A prospective cohort study of healthcare visits and rehospitalizations after discharge of patients with community-acquired pneumonia. Respirology. 2011 Oct;16(7):1119–26. doi: https://doi.org/10.1111/j.1440-1843.2011.02017.x
  5. Daniel P, Bewick T, McKeever TM, Roberts M, Ashton D, Smith D, et al. Healthcare reconsultation in working-age adults following hospitalisation for community-acquired pneumonia. Clin Med (Lond). 2018 Feb;18(1):41–6. doi: https://doi.org/10.7861/clinmedicine.18-1-41
  6. Aliberti S, Dela Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia. Lancet. 2021 Sep;398(10303):906–19. doi: https://doi.org/10.1016/S0140-6736(21)00630-9
  7. Pick HJ, Bolton CE, Lim WS, McKeever TM. Patient-reported outcome measures in the recovery of adults hospitalised with community-acquired pneumonia: a systematic review. Eur Respir J. 2019 Mar;53(3):1802165. doi: https://doi.org/10.1183/13993003.02165-2018
  8. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015 Jan;313(3):264–74. doi: https://doi.org/10.1001/jama.2014.18229
  9. Davydow DS, Hough CL, Levine DA, Langa KM, Iwashyna TJ. Functional disability, cognitive impairment, and depression after hospitalization for pneumonia. Am J Med. 2013 Jul;126(7):615–24.e5. doi: https://doi.org/10.1016/j.amjmed.2012.12.006
  10. Chalitsios CV, Baskaran V, Harwood RH, Lim WS, McKeever TM. Incidence of cognitive impairment and dementia after hospitalisation for pneumonia: a UK population-based matched cohort study. ERJ Open Res. 2023 May;9(3):00328–02022. doi: https://doi.org/10.1183/23120541.00328-2022
  11. El Moussaoui R, Opmeer BC, de Borgie CA, Nieuwkerk P, Bossuyt PM, Speelman P, et al. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia. Chest. 2006 Oct;130(4):1165–72. doi: https://doi.org/10.1378/chest.130.4.1165
  12. Metlay JP, Fine MJ, Schulz R, Marrie TJ, Coley CM, Kapoor WN, et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med. 1997 Jul;12(7):423–30. doi: https://doi.org/10.1046/j.1525-1497.1997.00074.x
  13. Glick HA, Miyazaki T, Hirano K, Gonzalez E, Jodar L, Gessner BD, et al. One-Year Quality of Life Post-Pneumonia Diagnosis in Japanese Adults. Clin Infect Dis. 2021 Jul;73(2):283–90. doi: https://doi.org/10.1093/cid/ciaa595
  14. Dang TT, Eurich DT, Weir DL, Marrie TJ, Majumdar SR. Rates and risk factors for recurrent pneumonia in patients hospitalized with community-acquired pneumonia: population-based prospective cohort study with 5 years of follow-up. Clin Infect Dis. 2014 Jul;59(1):74–80. doi: https://doi.org/10.1093/cid/ciu247
  15. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022 May;28(5):911–23. doi: https://doi.org/10.1038/s41591-022-01810-6
  16. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 Mar;21(3):133–46. doi: https://doi.org/10.1038/s41579-022-00846-2
  17. Kruckow KL, Zhao K, Bowdish DM, Orihuela CJ. Acute organ injury and long-term sequelae of severe pneumococcal infections. Pneumonia. 2023 Mar;15(1):5. doi: https://doi.org/10.1186/s41479-023-00110-y
  18. Lettinga KD, Verbon A, Nieuwkerk PT, Jonkers RE, Gersons BP, Prins JM, et al. Health-related quality of life and posttraumatic stress disorder among survivors of an outbreak of Legionnaires disease. Clin Infect Dis. 2002 Jul;35(1):11–7. doi: https://doi.org/10.1086/340738
  19. Marrie TJ, Beecroft M, Herman-Gnjidic Z, Poulin-Costello M. Symptom resolution in patients with Mycoplasma pneumoniae pneumonia. Can Respir J. 2004;11(8):573–7. doi: https://doi.org/10.1155/2004/659187
  20. Graham FF, Finn N, White P, Hales S, Baker MG. Global Perspective of Legionella Infection in Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Observational Studies. Int J Environ Res Public Health. 2022 Feb;19(3):1907. doi: https://doi.org/10.3390/ijerph19031907
  21. Roed T, Schønheyder HC, Nielsen H. Predictors of positive or negative legionella urinary antigen test in community-acquired pneumonia. Infect Dis (Lond). 2015 Jul;47(7):484–90. doi: https://doi.org/10.3109/23744235.2015.1021830
  22. Viasus D, Di Yacovo S, Garcia-Vidal C, Verdaguer R, Manresa F, Dorca J, et al. Community-acquired Legionella pneumophila pneumonia: a single-center experience with 214 hospitalized sporadic cases over 15 years. Medicine (Baltimore). 2013 Jan;92(1):51–60. doi: https://doi.org/10.1097/MD.0b013e31827f6104
  23. Allgaier J, Lagu T, Haessler S, Imrey PB, Deshpande A, Guo N, et al. Risk Factors, Management, and Outcomes of Legionella Pneumonia in a Large, Nationally Representative Sample. Chest. 2021 May;159(5):1782–92. doi: https://doi.org/10.1016/j.chest.2020.12.013
  24. Cunha BA, Burillo A, Bouza E. Legionnaires’ disease. Lancet. 2016 Jan;387(10016):376–85. doi: https://doi.org/10.1016/S0140-6736(15)60078-2
  25. Raoult D, Marrie T, Mege J. Natural history and pathophysiology of Q fever. Lancet Infect Dis. 2005 Apr;5(4):219–26. doi: https://doi.org/10.1016/S1473-3099(05)70052-9
  26. van Loenhout JA, van Tiel HH, van den Heuvel J, Vercoulen JH, Bor H, van der Velden K, et al. Serious long-term health consequences of Q-fever and Legionnaires’ disease. J Infect. 2014 Jun;68(6):527–33. doi: https://doi.org/10.1016/j.jinf.2014.01.004
  27. Fischer FB, Bigler M, Mäusezahl D, Hattendorf J, Egli A, Julian TR, et al.; SwissLEGIO Hospital Network. Legionnaires’ disease in Switzerland: rationale and study protocol of a prospective national case-control and molecular source attribution study (SwissLEGIO). Infection. 2023 Oct;51(5):1467–79. doi: https://doi.org/10.1007/s15010-023-02014-x
  28. Schweizerische Gesellschaft für Infektiologie. SGInf-Guidelines: Ambulant-erworbene Pneumonie CAP. Available from: https://ssi.guidelines.ch/guideline/3007/de
  29. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727–36. doi: https://doi.org/10.1007/s11136-011-9903-x
  30. World Health Organization. Regional Office for Europe. Wellbeing measures in primary health care/the DepCare Project: report on a WHO meeting: Stockholm, Sweden, 12–13 February 1998. Copenhagen: World Health Organization. Regional Office for Europe 1998. Contract No.: WHO/EURO:1998-4234-43993-62027. Available from: https://iris.who.int/handle/10665/349766
  31. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988 Mar;93(3):580–6. doi: https://doi.org/10.1378/chest.93.3.580
  32. Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. J Psychosom Res. 2003 Apr;54(4):345–52. doi: https://doi.org/10.1016/S0022-3999(02)00392-6
  33. El Moussaoui R, Opmeer BC, Bossuyt PM, Speelman P, de Borgie CA, Prins JM. Development and validation of a short questionnaire in community acquired pneumonia. Thorax. 2004 Jul;59(7):591–5. doi: https://doi.org/10.1136/thx.2003.015107
  34. Wyrwich KW, Yu H, Sato R, Powers JH. Observational longitudinal study of symptom burden and time for recovery from community-acquired pneumonia reported by older adults surveyed nationwide using the CAP Burden of Illness Questionnaire. Patient Relat Outcome Meas. 2015 Jul;6:215–23.
  35. Lamping DL, Schroter S, Marquis P, Marrel A, Duprat-Lomon I, Sagnier PP. The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia. Chest. 2002 Sep;122(3):920–9. doi: https://doi.org/10.1378/chest.122.3.920
  36. Horn A, Krist L, Lieb W, Montellano FA, Kohls M, Haas K, et al. Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP). Infection. 2021 Dec;49(6):1277–87. doi: https://doi.org/10.1007/s15010-021-01707-5
  37. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS One. 2021 Jul;16(7):e0254523. doi: https://doi.org/10.1371/journal.pone.0254523
  38. Zhang H, Huang C, Gu X, Wang Y, Li X, Liu M, et al. 3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study. Lancet Respir Med. 2024 Jan;12(1):55–66. doi: https://doi.org/10.1016/S2213-2600(23)00387-9
  39. Serrano L, Ruiz LA, Perez-Fernandez S, España PP, Gomez A, Gonzalez B, et al. Short- and long-term prognosis of patients with community-acquired Legionella or pneumococcal pneumonia diagnosed by urinary antigen testing. Int J Infect Dis. 2023 Sep;134:106–13. doi: https://doi.org/10.1016/j.ijid.2023.05.065
  40. Gamage SD, Ross N, Kralovic SM, Simbartl LA, Roselle GA, Berkelman RL, et al. Health after Legionnaires’ disease: A description of hospitalizations up to 5 years after Legionella pneumonia. PLoS One. 2021 Jan;16(1):e0245262. doi: https://doi.org/10.1371/journal.pone.0245262
  41. Cassini A, Colzani E, Pini A, Mangen MJ, Plass D, McDonald SA, et al.; BCoDE consortium. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Euro Surveill. 2018 Apr;23(16):17–00454. doi: https://doi.org/10.2807/1560-7917.ES.2018.23.16.17-00454
  42. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, et al. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140–9. doi: https://doi.org/10.3201/eid2701.190676
  43. Bolliger R, Neeser O, Merker M, Vukajlovic T, Felder L, Fiumefreddo R, et al. Validation of a Prediction Rule for Legionella Pneumonia in Emergency Department Patients. Open Forum Infect Dis. 2019 Jun;6(7):ofz268. doi: https://doi.org/10.1093/ofid/ofz268